Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
14,130.309 CLP
10.57 T CLP
44.95 T CLP
848.58 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG01NBMVZG8
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6003479
Eli Lilly and Company 4.9% 12-FEB-2032Yield to maturity
—
Maturity date
Feb 12, 2032
LLY6153403
Eli Lilly and Company 4.9% 15-OCT-2035Yield to maturity
—
Maturity date
Oct 15, 2035
LLY5546986
Eli Lilly and Company 4.7% 27-FEB-2033Yield to maturity
—
Maturity date
Feb 27, 2033
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047Yield to maturity
—
Maturity date
May 15, 2047
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053Yield to maturity
—
Maturity date
Feb 27, 2053
LLY6003481
Eli Lilly and Company 4.75% 12-FEB-2030Yield to maturity
—
Maturity date
Feb 12, 2030
LLY.GW
Eli Lilly and Company 5.55% 15-MAR-2037Yield to maturity
—
Maturity date
Mar 15, 2037
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
—
Maturity date
Feb 27, 2063
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054Yield to maturity
—
Maturity date
Feb 9, 2054
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054Yield to maturity
—
Maturity date
Aug 14, 2054
LLY6153505
Eli Lilly and Company FRN 15-OCT-2028Yield to maturity
—
Maturity date
Oct 15, 2028
See all LLYCL bonds
Curated watchlists where LLYCL is featured.
Frequently Asked Questions
The current price of LLYCL is 703,500.000 CLP — it hasn't changed in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BCS exchange Eli Lilly and Company stocks are traded under the ticker LLYCL.
LLYCL stock has fallen by −0.83% compared to the previous week, the month change is a 13.10% rise, over the last year Eli Lilly and Company has showed a −18.22% decrease.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLYCL price has a max estimate of 1,156,462.59 CLP and a min estimate of 680,272.11 CLP. Watch LLYCL chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLYCL reached its all-time high on Jan 24, 2025 with the price of 941,000.000 CLP, and its all-time low was 608,400.000 CLP and was reached on Aug 12, 2025. View more price dynamics on LLYCL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LLYCL stock is 3.23% volatile and has beta coefficient of 0.61. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of 690.40 T, it has increased by 5.97% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
LLYCL earnings for the last quarter are 5.90 K CLP per share, whereas the estimation was 5.24 K CLP resulting in a 12.70% surprise. The estimated earnings for the next quarter are 6.18 K CLP per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 14.55 T CLP, despite the estimated figure of 13.76 T CLP. In the next quarter, revenue is expected to reach 15.58 T CLP.
LLYCL net income for the last quarter is 5.30 T CLP, while the quarter before that showed 2.63 T CLP of net income which accounts for 101.30% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLYCL dividends are paid quarterly. The last dividend per share was 1.45 K CLP. As of today, Dividend Yield (TTM)% is 0.77%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 11, 2025, the company has 47 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 22.76 T CLP, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLYCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the neutral signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.